| scholarly article | Q13442814 |
| P50 | author | Xin Xu | Q93104491 |
| P2093 | author name string | Michael Hensel | |
| Wael Abdel Halim Hegazy | |||
| Leonid Metelitsa | |||
| P2860 | cites work | Bacterial flagella and type III secretion systems | Q28214315 |
| Immunology of Gut Mucosal Vaccines | Q28972559 | ||
| The type III secretion injectisome | Q29617944 | ||
| T cell receptor antagonist peptides induce positive selection | Q29618820 | ||
| Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens | Q30990189 | ||
| Use of live bacterial vaccine vectors for antigen delivery: potential and limitations | Q31887727 | ||
| Salmonella pathogenicity island 2-mediated overexpression of chimeric SspH2 proteins for simultaneous induction of antigen-specific CD4 and CD8 T cells | Q33559019 | ||
| Salmonella: immune responses and vaccines | Q34177847 | ||
| Intracellular bacteria as targets and carriers for vaccination | Q34280918 | ||
| Efficacy of intracellular activated promoters for generation of Salmonella-based vaccines | Q34290850 | ||
| Novel cancer vaccine based on genes of Salmonella pathogenicity island 2. | Q34357503 | ||
| Bacterial type III translocation: a unique mechanism for cytosolic display of heterologous antigens by attenuated Salmonella | Q35130643 | ||
| Immunity to Salmonella from a dendritic point of view | Q35608895 | ||
| T cell responses to Listeria monocytogenes | Q35702996 | ||
| Process of protein transport by the type III secretion system | Q35980175 | ||
| Manipulating cellular transport and immune responses: dynamic interactions between intracellular Salmonella enterica and its host cells. | Q36447552 | ||
| Salmonella pathogenicity islands in host specificity, host pathogen-interactions and antibiotics resistance of Salmonella enterica. | Q36917630 | ||
| Salmonella type III-mediated heterologous antigen delivery: a versatile oral vaccination strategy to induce cellular immunity against infectious agents and tumors. | Q36919064 | ||
| Rational design of Salmonella recombinant vaccines | Q36948880 | ||
| Salmonellae interplay with host cells | Q37008201 | ||
| Salmonella--the ultimate insider. Salmonella virulence factors that modulate intracellular survival. | Q37602205 | ||
| Type III secretion of Salmonella enterica serovar Typhimurium translocated effectors and SseFG. | Q39654226 | ||
| Recombinant vaccines based on translocated effector proteins of Salmonella Pathogenicity Island 2. | Q40248092 | ||
| Systematic analysis of the SsrAB virulon of Salmonella enterica | Q41775111 | ||
| Functional analysis of the Salmonella pathogenicity island 2-mediated inhibition of antigen presentation in dendritic cells | Q43250958 | ||
| Antigen presentation capacity and cytokine production by murine splenic dendritic cell subsets upon Salmonella encounter | Q43902809 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Salmonella enterica | Q2264864 |
| P304 | page(s) | 1193-1202 | |
| P577 | publication date | 2012-01-17 | |
| P1433 | published in | Infection and Immunity | Q6029193 |
| P1476 | title | Evaluation of Salmonella enterica type III secretion system effector proteins as carriers for heterologous vaccine antigens | |
| P478 | volume | 80 |
| Q64106013 | A Live Vaccine Delivering PcrV through the Type III Secretion System Protects against Pseudomonas aeruginosa |
| Q36883886 | A safe bacterial microsyringe for in vivo antigen delivery and immunotherapy. |
| Q38151981 | Aeromonas salmonicida subsp. salmonicida in the light of its type-three secretion system |
| Q37842893 | An autotransporter display platform for the development of multivalent recombinant bacterial vector vaccines |
| Q38034843 | Bacterial vectors for active immunotherapy reach clinical and industrial stages |
| Q34438443 | Effective cancer vaccine platform based on attenuated salmonella and a type III secretion system |
| Q92984654 | Factors affecting Salmonella-based combination immunotherapy for prevention of type 1 diabetes in non-obese diabetic mice |
| Q36790792 | Identification of salmonella pathogenicity island-2 type III secretion system effectors involved in intramacrophage replication of S. enterica serovar typhimurium: implications for rational vaccine design. |
| Q58692386 | Impact of Salmonella enterica Type III Secretion System Effectors on the Eukaryotic Host Cell |
| Q40633254 | Improved delivery of the OVA-CD4 peptide to T helper cells by polymeric surface display on Salmonella |
| Q38734240 | Intracellular delivery of biologic therapeutics by bacterial secretion systems. |
| Q47733620 | Lessons Learned from Protective Immune Responses to Optimize Vaccines against Cryptosporidiosis |
| Q38152473 | Live-attenuated bacteria as a cancer vaccine vector |
| Q47399527 | Rationale redesign of type III secretion systems: toward the development of non-pathogenic E. coli for in vivo delivery of therapeutic payloads |
| Q44631677 | Salmonella cross-protective vaccines: fast-forward to the next generation of food safety. |
| Q33801051 | The delicate balance in genetically engineering live vaccines |
Search more.